Dr. Heaton brings a 30-year career in pharmaceutical discovery, development, and translational studies to Cure JM, and most recently served as the CEO and President of Heaton-Brown Life Sciences and Novogen North America. Dr. Heaton, ushered several oncology compounds from the laboratory through Phase I, II and III clinical trials.
As CSO, Dr. Heaton serves as Cure JM’s science and research leader, proactively driving the growth and effectiveness of Cure JM’s grants and clinical research program. He serves as key staff to Cure JM’s Research Committee and Medical Advisory Board, providing strategic oversight, guidance, and leadership in executing Cure JM’s Research Priorities.
Dr. Heaton is the senior author on over 100, globally granted-patents, covering a wide range of molecular architectures and diseases and has published multiple papers in peer-reviewed scientific journals.
Dr. Heaton received his Bachelor of Science degree from the University of Tasmania, his doctorate from James Cook University of North Queensland, his MBA from Melbourne Business School, and completed a sabbatical at Imperial College, London.
He currently lives in Florida.